Inloggad som:
FLIRT-studien
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
FLIRT-studien
Primary treatment of follicular lymphoma with rituximab-lenalidomide-tafasitamab for high-risk disease and rituximab-lenalidomide with a 1:1 randomization to tafasitamab for low-risk disease: a phase II study – NLG-FLIRT
Primary treatment of follicular lymphoma with rituximab-lenalidomide-tafasitamab for high-risk disease and rituximab-lenalidomide with a 1:1 randomization to tafasitamab for low-risk disease: a phase II study – NLG-FLIRT
PLACEHOLDER
Mer information om studien för vårdgivare
Studien ändrades senast av: studyjohanna (2025-06-16)